Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Gill, Sarvarinder Kaur [1 ]
Fleming, Erika [2 ]
Gebre, Helen [1 ]
Bangolo, Ayrton, I [3 ]
Siegel, David S. [4 ,5 ]
Vesole, David H. [6 ]
Biran, Noa [6 ]
Parmar, Harsh [6 ]
Phull, Pooja [6 ]
机构：
[1] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Hackensack Meridian Sch Med, Nutley, NJ USA
[3] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Edgewater, NJ USA
[4] Hackensack Meridian Hlth, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA
[5] Ctr Discovery & Innovat, Hackensack, NJ USA
[6] Hackensack Univ Med Ctr, Div Multiple Myeloma, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-210350
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7047 / 7048
页数：2
相关论文
共 50 条
  • [21] Practical management of patients with relapsed/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in monumenTAL-1
    Catamero, Donna
    Purcell, Kiah
    Ray, Chloe
    Giacoia, Leora
    Leahey, Sheryl
    Born, Patricia
    Kruyswijk, Sandy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S314 - S315
  • [22] Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial
    Hao Yao
    Shi-hui Ren
    Lin-hui Wang
    Ming-qiang Ren
    Jiao Cai
    Dan Chen
    Ying He
    Si-han Lai
    Bai-tao Dou
    Meng-jiao Li
    Yan-ling Li
    Ya-li Cen
    Alex H. Chang
    Yi Su
    Ling Qiu
    Fang-yi Fan
    Journal of Hematology & Oncology, 18 (1)
  • [23] Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
    Mancia, Stefania Stefania
    Farrell, Annamaria
    Louw, Karen
    Florendo, Erika
    Aronson, Elizabeth
    Purcell, Kiah
    Catamero, Donna D.
    Escalon, Juliet
    Thomas, Joanne
    Aponte, Annel
    Lamb, Angela
    Kirke, Diana
    Lucas, Aimee
    Jagannath, Sundar
    Cho, Hearn Jay
    Parekh, Samir
    Richter, Joshua
    Sanchez, Larysa
    Chari, Ajai
    BLOOD, 2021, 138
  • [24] MANAGEMENT CONSIDERATIONS FOR DERMATOLOGIC TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA
    Esler, Elaine
    Ray, Chloe
    Hefner, Kayla
    O'Rourke, Lisa
    Gray, Kathleen
    McCluggage, Julie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [25] Combined GPRC5D and BCMA-targeted T-cell Redirecting Therapy in the Treatment of RRMM
    Godby, Kelly
    Bal, Susan
    Giri, Smit
    Ravi, Gayathri
    Joiner, Laura
    Hagedorn, Caitlin
    Costa, Luciano
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S55 - S56
  • [26] Management considerations for dermatologic toxicities associated with talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
    Purcell, Kiah
    Catamero, Donna
    Dai, Victoria
    Feuer, Julia
    Giacoia, Leora
    Leon, Yan
    Lurie, Alaina
    Mitchell, Emily
    Ray, Chloe
    Urena, Annel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S312 - S313
  • [27] Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)xCD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study
    Van De Donk, Niels W. C. J.
    Krishnan, Amrita
    Oriol, A.
    Berdeja, Jesus G.
    Rodriguez-Otero, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Costa, Luciano
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi
    Russell, Jeffery
    Goldberg, Jenna
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S16 - S17
  • [28] MANAGEMENT CONSIDERATIONS FOR ORAL TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Shenoy, Samantha
    Leahey, Sheryl
    Catamero, Donna
    O'Rourke, Lisa
    Gray, Kathleen
    Rogers, Stephanie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [29] Real World Experience of Standard of Care Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
    Grajales-cruz, Ariel
    Graeter, Allison
    Hansen, Doris
    Puglianini, Omar Castaneda
    Vazquez-Martinez, Mariola
    Blue, Brandon
    Liu, Hien
    Ochoa-Bayona, Jose
    Freeman, Ciara
    Locke, Frederick
    Nishihori, Taiga
    Shain, Kenneth
    Baz, Rachid
    Alsina, Melissa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S56 - S56
  • [30] A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Krishnan, Amrita
    BLOOD, 2020, 136
12345